Showing papers in "Blood in 2009"

TL;DR: The classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.

TL;DR: An International Working Group of recognized expert clinicians convened a 2-day structured meeting to define standard terminology and definitions for primary ITP and its different phases and criteria for the grading of severity, and clinically meaningful outcomes and response.

TL;DR: It is suggested that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.

TL;DR: T cells expressing highly reactive TCRs mediate cancer regression in humans and target rare cognate-antigen-containing cells throughout the body, a finding with important implications for the gene therapy of cancer.

TL;DR: The results document how hFcgammaR specificity and affinity may account for the biological activities of antibodies and highlight the role of specific hF cgammaRs in the therapeutic and pathogenic effects of antibodies in disease.

TL;DR: It is reported that reduction of tumor burden after ablative RT depends largely on T-cell responses, and the need for new strategies that not only reduce tumor burden but also enhance the role of antitumor immunity is emphasized.

TL;DR: A novel experimental and computational approach is developed to measure TCR CDR3 diversity based on single-molecule DNA sequencing, and it is found that total TCRbeta receptor diversity is at least 4-fold higher than previous estimates, and the diversity in the subset of CD45RO(+) antigen-experienced alphabeta T cells is at at least 10-foldHigher than previously estimates.

TL;DR: Novel molecular markers are needed to better predict progression to MM in patients with MGUS and in approximately half the study population, the M-protein concentration and involved FLC-ratio levels showed a yearly increase prior to MM diagnosis.

TL;DR: Standard intensive treatment improves early death rates and long-term survival compared with palliation and most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction.

TL;DR: Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis,1 patient with an idiopathic autoimmune pancytopenia, and 1 patientwith immune thrombocytopenIA developed PML after treatment with rituximab and other agents from 1997 to 2008.

TL;DR: What has been learned about the Toll-like receptors, which play an essential part in the perception of microbes and shape the complex host responses that occur during infection, are described.

TL;DR: This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.

TL;DR: Novel functional links between miRNAs and aberrant DNA hypermethylation in acute myeloid leukemia and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds are provided.

TL;DR: It is demonstrated that human blood monocytes release processed IL-1beta after a one-time stimulation with either TLR2 or TLR4 ligands, resulting from constitutively activated caspase-1 and release of endogenous adenosine triphosphate.

TL;DR: scientific and clinical rationale for developing novel immune-boosting strategies based on promoting the Th17 cell population in cancer patients are provided and inhibition of Th17 cells represents a novel immune evasion mechanism are provided.

TL;DR: The development of a highly specific and sensitive novel test for the typing of amyloidosis in routine clinical biopsy specimens that combines specific sampling by laser microdissection (LMD) and analytical power of tandem mass spectrometry (MS)-based proteomic analysis.

TL;DR: Plerixafor and G- CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone.

TL;DR: In this paper, the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) was evaluated.

TL;DR: It is suggested that primary ITP is also best thought of as an autoimmune syndrome and better understanding of pathogenesis and tolerance checkpoint defects leading to autoantibody formation may facilitate patient-specific approaches to diagnosis and management.

TL;DR: The ability to reprogram cells from human blood will allow the generation of patient-specific stem cells for diseases in which the disease-causing somatic mutations are restricted to cells of the hematopoietic lineage.

TL;DR: CML-CP pts responding to IM had a low overall risk of progression to AP/BC and the safety profile of IM remains unchanged after 8 yr, with no previously unreported AEs identified over the past 36 mo.

TL;DR: A 4-stage model ofNK-cell maturation appears to be associated with a progressive acquisition of NK-cell effector functions.

TL;DR: It is concluded that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma, however, the underlying features responsible for these differences remain to be defined.

TL;DR: The role of MSCs in inhibiting early DC maturation is emphasized and the molecular mechanisms responsible for the inhibitory effect are identified, including PGE(2) and not IL-6 represents the key inhibitory mediator.

TL;DR: Primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, still remain poorly understood are synthesized.

TL;DR: The diagnosis of MYC+ DLBCL is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in all patients withDLBCL.

TL;DR: The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clinical FLT3 inhibitor.

TL;DR: Cutaneous lymphomas rates vary markedly by race and sex, supporting the notion that they represent distinct disease entities.

TL;DR: Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely, and is associated with poorer response to imatinib.

TL;DR: A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL 2-targeted therapy.